Ontology highlight
ABSTRACT:
SUBMITTER: Radhakrishnan VS
PROVIDER: S-EPMC10808788 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature
Radhakrishnan Vivek S VS Davies Andrew J AJ
Frontiers in immunology 20240111
The advent of immunotherapy in lymphomas, beginning with Rituximab, have led to paradigm shifting treatments that are increasingly bringing a greater number of affected patients within the ambit of durable disease control and cure. Bispecific antibodies harness the properties of the immunoglobulin antibody structure to design molecules which, apart from engaging with the target tumour associated antigen, engage the host's T-cells to cause tumour cell death. Mosunetuzumab, an anti-CD20 directed b ...[more]